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Background: In recent years, maintenance chemotherapy is increasingly being recognized as a new treatment
strategy to improve the outcome of advanced non-small cell lung cancer (NSCLC). However, the optimal
maintenance strategy is still controversial. Gemcitabine is a promising candidate for single-agent maintenance
therapy because of little toxicity and good tolerability. We have conducted a randomized phase II study to evaluate
the validity of single-agent maintenance chemotherapy of gemcitabine and to compare continuation- and switch-
maintenance.
Methods: Chemonaïve patients with stage IIIB/IV NSCLC were randomly assigned 1:1 to either arm A or B. Patients
received paclitaxel (200 mg/m2, day 1) plus carboplatin (AUC 6 mg/mL/min, day 1) every 3 weeks in arm A, or
gemcitabine (1000 mg/m2, days 1 and 8) plus carboplatin (AUC 5 mg/mL/min, day1) every 3 weeks in arm B.
Non-progressive patients following 3 cycles of induction chemotherapy received maintenance gemcitabine (1000
mg/m2, days 1 and 8) every 3 weeks. (Trial registration: UMIN000008252)
Results: The study was stopped because of delayed accrual at interim analysis. Of the randomly assigned 50
patients, 49 except for one in arm B were evaluable. Median progression-free survival (PFS) was 4.6 months for arm
A vs. 3.5 months for arm B (HR = 1.03; 95% CI, 0.45–2.27; p = 0.95) and median overall survival (OS) was 15.0 months
for arm A vs. 14.8 months for arm B (HR = 0.79; 95% CI, 0.40–1.51; p = 0.60), showing no difference between the
two arms. The response rate, disease control rate, and the transit rate to maintenance phase were 36.0% (9/25),
64.0% (16/25), and 48% (12/25) for arm A vs. 16.7% (4/24), 50.0% (12/24), and 33% (8/24) for arm B, which were also
statistically similar between the two arms (p = 0.13, p = 0.32, and p = 0.30, respectively). Both induction regimens
were tolerable, except that more patients experienced peripheral neuropathy in arm A. Toxicities during the
maintenance phase were also minimal.
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Conclusion: Survival and overall response were not significantly different between the two arms. Gemcitabine may
be well-tolerable and feasible for maintenance therapy.
Keywords: Carboplatin, Gemcitabine, Paclitaxel, Switch-maintenance, Continuation-maintenance, Non-small cell
lung cancer (NSCLC), Randomized phase IIBackground
Lung cancer is the leading cause of cancer death world-
wide [1]. Non-small cell lung cancer (NSCLC) accounts
for 85% of all lung cancer cases and most of them are
found to have locally advanced or metastatic diseases at
the time of diagnosis. However, the efficacy of standard
platinum-based regimens in the first-line setting for
advanced NSCLC has reached a plateau. Recently, main-
tenance therapy is increasingly being approved as a new
treatment paradigm to improve the outcome for advanced
NSCLC. New generation cytotoxic agents such as pacli-
taxel [2], vinorelbine [3], docetaxel [4], gemcitabine [5,6],
and pemetrexed [7], and molecular-targeted agents such
as gefitinib [8], erlotinib [9] and bevacizumab [10,11], have
been evaluated for their efficacy as single-agent mainten-
ance therapy. Among these wide range of agents, gemcita-
bine (GemzarW, Eli Lilly & Co., Indianapolis, IN, USA)
is a pyrimidine antimetabolite that has demonstrated
antitumor activities in diverse tumor types. It is not
only one of the standard drugs in the regimens for un-
treated advanced-stage NSCLC [12-15], but also active
against recurrent NSCLC after platinum-based chemo-
therapy [16-18]. In addition to these antitumor activities,
it is also one of the promising candidates for maintenance
use because of its low cumulative toxicities [5,6].
Maintenance chemotherapy can be broadly categorized
as switch-maintenance and continuation-maintenance.
The former is defined as maintenance treatment with dif-
ferent drugs from those used in the induction regimen,
while the latter is with one or two of the drugs used in
the induction regimen. In the latest meta-analysis of
maintenance chemotherapy in advanced NSCLC [19],
the differences in overall survival (OS) and progression-
free survival (PFS) between the two maintenance strat-
egies were not statistically significant. However, no study
has compared these two maintenance strategies directly.
Therefore, we conducted an investigational randomized
phase II study to evaluate the validity of gemcitabine for
single-agent maintenance chemotherapy and to compare
switch- and continuation-maintenance.Method
Objectives and study design
This trial was a randomized, open-label, multi-centered,
phase II study. The primary objective was to investigate
PFS. Secondary objectives were to investigate theobjective response rate (RR) and safety. The study proto-
col was approved by each institutional ethics committee
and adhered to the principles outlined in the Guideline
for Good Clinical Practice (January 1997) and Declar-
ation of Helsinki (1996). Written informed consent was
obtained from all patients before commencement of the
study.
Patient selection
Patients were enrolled when they met all the following
entry criteria: (1) histologically or cytologically confirmed
NSCLC with chemotherapy-naïve stage IIIB/IV; (2) 20 ≤
age < 75 years; (3) having measurable disease according to
Response Evaluation Criteria in Solid Tumors (RECIST)
version 1.0; (4) an Eastern Cooperative Oncology Group
(ECOG) performance status (PS) grade of 0–1; (5) adequate
hematologic (absolute white blood cell count ≥ 4000/μL,
neutrophil count ≥ 1500/μL, platelets ≥ 100,000/μL, and
hemoglobin ≥ 10.0 g/dL), renal (serum creatinine ≤ 1.2
mg/dL and creatinin clearance calculated by Cockcroft-
Gault formula ≥ 60 mL/min), liver (serum total bilirubin
≤ 1.5 mg/dL, aspartate aminotransferase and alanine ami-
notransferase ≤ 100 IU/L), and respiratory (SpO2 ≥ 95%
under room air) functions; (6) estimated life expectancy of
more than 3 months; (7) written informed consent. Patients
with asymptomatic brain metastases were also eligible. On
the other hand, exclusion criteria were; (1) clinically signifi-
cant complications or unstable medical conditions; (2) re-
currence after resection, and curative or palliative thoracic
radiotherapy for primary tumor irrespective of irradiation
dose; (3) palliative extra-thoracic radiotherapy within 2
weeks; (4) pregnancy, lactation, suspicion of being preg-
nant; (5) other neoplasm with progression-free time under
5 years.
Treatment plan
Patients were randomly assigned to arm A or B using
dynamic allocation by institution, gender, and PS. In arm
A, carboplatin (AUC 6 mg/mL/min, day 1) and paclitaxel
(200 mg/m2, day 1) were administered intravenously (i.v.)
every 3 weeks. In arm B, carboplatin (AUC 5 mg/mL/min,
day 1) and gemcitabine (1000 mg/m2, days 1 and 8) were
i.v. administered every 3 weeks. The number of cycles for
induction chemotherapy was defined 3 by the following
two reasons; (1) no evidence for additional clinical benefit
by continuing cisplatin-containing chemotherapy beyond
Table 1 Patients’ characteristics
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number of administered platinum doublet chemotherapy
was only 3 in Japanese Four-Arm Cooperative Study
(FACS) [13]. After 3 cycles, non-progressive patients
underwent maintenance gemcitabine (1000 mg/m2, days 1
and 8) every 3 weeks. Treatment was continued until dis-
ease progression, unacceptable toxicity, or withdrawal of
consent. The glomerular filtration rate and carboplatin
dose were calculated using Cockcroft-Gault and Calvert
formula, respectively. Serum creatinine concentrations of
the enzyme method were calibrated to those of the non-
compensated Jaffé’s method by adding 0.2 mg/dL. Unless
all the starting criteria defined in the protocol were met,
administration of drugs on days 1 and 8 was postponed.
Discontinuation criteria of protocol treatment included;
(1) delay of the start of the next course longer than one
week, (2) delay of gemcitabine administration on day 8
longer than 2 weeks, (3) necessity of third-time dose reduc-
tion, (4) documented disease progression and (5) patient’s
refusal to continue the protocol therapy.
Assessments
Required baseline assessments included chest and ab-
dominal computed tomography (CT), cranial CT or
magnetic resonance imaging (MRI), and bone scintig-
raphy or positron emission tomography (PET) within 4
weeks before enrollment. Overall response was evaluated
according to RECIST version 1.0 after the first and third
cycles of induction chemotherapy, and then every 2
cycles during maintenance chemotherapy. Toxicity was
graded by the National Cancer Institute-Common
Terminology Criteria for Adverse Events (NCI-CTCAE)
version 3.0.
Statistical analyses
The sample size was based on the assumption that the
hazard ratio (HR) of arm B to arm A for PFS would be
approximately 1.5. To select a better treatment arm,
with two-sided alpha of 5% and a power of 90%, at least
94 evaluable patients and 74 non-progressive responders
were needed. Given the possibility of deviation from as-
sessment, 100 patients (50 per arm) were necessary. The
evaluable population for overall response included all
patients, defined as those without major protocol viola-
tion, who had received at least one cycle chemotherapy
and had at least two response assessment over 6 weeks
after the enrollment unless determination of objective
progressive disease (PD). Patients who received any
protocol therapy without major protocol violation were
considered evaluable for PFS, OS and safety. PFS and
OS were evaluated by Kaplan-Meier method. Differences
between the two arms were evaluated by Pearson’s chi-
square test and the log-rank test, and the HR was calcu-
lated by Cox regression model.Results
Although enrollment to this study was planned to
complete within 2 years, only half the required samples
were accrued in the time-period. During the study
period, pemetrexed and bevacizumab became commer-
cially available in Japan in May 2009 and November
2009, respectively. Therefore, this study was terminated
at that time because of delayed accrual and fear of
biased histology in favor of squamous cell carcinoma.
Patient demographics
From December 2007 to November 2009, a total of 50
patients, 25 randomly assigned to each arm, were enrolled
from seven medical institutions. The baseline characteris-
tics were similar between the two arms, except more male
patients were enrolled in arm A (Table 1). Data on smok-
ing habits and the epidermal growth factor receptor
(EGFR) mutation status were not collected.
Treatment
One patient in arm B was excluded from analyses be-
cause of a major protocol violation during induction
phase. Of the rest 49 evaluable patients, 68% (17/25) in
arm A and 50% (12/24) in arm B completed 3 cycles of
induction chemotherapy.
Eight patients in arm A dropped out during induction
phase because of PD (n = 5), physician’s decision (n = 2),
persistent anemia (n = 1), while 13 in arm B did because
of PD (n = 3), hematologic AEs (n = 4), persistent ALT
elevation (n = 2), physician’s decision (n = 1), and compli-
cated disease (n = 3). Complicated diseases included
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surgery, aspiration pneumonia and pyothorax that
required hospitalization and antibiotics therapy. During
transition from completion of induction phase to start of
maintenance phase, 5 patients in arm A and 3 in arm B
dropped out. In arm A, 3 patients resulted in PD, one
kept SD but failed to recover anemia, and one achieved
PR but suffered from bacterial pneumonia at the end of
induction phase. In arm B, 2 patients resulted in PD at
the end of induction phase despite having kept SD dur-
ing induction phase, and one kept SD after induction
phase but rapidly progressed until commencement of
maintenance phase.
Finally, only 12 patients (48%) in arm A and 8 (33%)
in arm B received gemcitabine maintenance therapy
(p = 0.25) (Figure 1). In both arms, there was no statisti-
cally significant difference in baseline characteristics be-
tween discontinued patients during induction phase andNo. of patients r
(n=50
arm A  (n=25)
25 treated with induction of 
Carboplatin+Paclitaxel
8  discontinued during induction phase
5  disease progression
2  physician decision
1  persistent anemia
17  completed induction chemotherapy
5  not treated with mentenance therapy
3  disease progression
1  persistent anemia
1  complicated disease
12 treated with maintenance therapy
12  discontined treatment
5 disease progression
2 physician’s dicision
2 complicated disease of bacterial 
penumonia
2 repeated or persistent neutropenia
1 patient’s refusal
Figure 1 CONSORT flow chart for the study.those received gemcitabine maintenance therapy (data not
shown). The average number of maintenance cycles deliv-
ered was 4.66 (range 1 to 11) in arm A and 6.75 (range 1
to 36) in arm B. All the 20 patients discontinued main-
tenance treatment as of November 2011 because of PD
(n = 11), physician’s decision (n = 3), patient’s refusal (n = 2),
and treatment-related AEs (n = 4; 2 repeated and/or
persistent neutropenia, 1 persistent anemia and 1 bac-
terial pneumonia).
Efficacy
The follow-up data were collected up to November 8th,
2011. The median follow-up time was 13.6 months
(95% CI, 8.6 to 17.1 months). At the time of the data
collection, 2 patients in arm A and 5 in arm B were still
alive. There was no patient still on maintenance treat-
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The median PFS and OS were 4.6 months (95% CI, 2.0
to not available) and 15.0 months (95% CI, 9.1 to 22.1
months) in arm A, and 3.5 months (95% CI, 1.9 to not
available) and 14.8 months (95% CI, 7.6 to 26.3 months)
in arm B, respectively. There was no statistical difference
between the two arms in terms of both PFS (p = 0.95)
and OS (p = 0.60) (Figure 2).
Overall response
In the induction therapy, 9 patients in arm A and 4 in
arm B achieved partial response (PR), and 7 and 8 kept
stable disease (SD), respectively. Consequently, the ob-
jective RR (36.0% vs. 16.7%, p = 0.13) and disease control
rate (DCR) (64.0% vs. 50.0%, p = 0.32) showed no signifi-
cant differences between the two arms (Table 2). Of 7
SD patients in arm A, one achieved PR after 3 cycles of
maintenance therapy. In 11 patients with squamous cell
carcinoma, one patient achieved PR, 2 kept SD and 3
progressed in arm A, while one patient kept SD, 2 pro-
gressed and 2 were not evaluated in arm B.
Safety
The incidental rates of grade 3-4 AEs were low. During
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Figure 2 Kaplan-Meier curves of PFS(a) and OS(b).(9 in arm A and 4 in arm B), grade 3 anemia (1 in arm B),
and grade 4 thrombocytopenia (2 in arm B) were
observed. Severe non-hematologic AEs included grade 3
skin rash (1 in each arm), grade 3 aminotransferase in-
crease (1 in arm A and 3 in arm B), grade 3 febrile neutro-
penia (1 in arm A), and grade 3 peripheral sensory
neuropathy (2 in arm A). Of all AEs, peripheral sensory
neuropathy, arthralgia, and myalgia peculiar to paclitaxel
were more frequently observed in arm A (p = 0.02, 0.04
and 0.02, respectively). Neutropenia also tended to be
more frequent in arm A (p = 0.06) (Table 3). During main-
tenance phase, hematologic AEs of grade 3-4 neutropenia
(3 in arm A and 2 in arm B), and grade 3
thrombocytopenia (1 in arm A) were observed. Non-
hematologic AEs of grade 3-4 were not experienced
(Table 4).
Post-protocol treatment
After the protocol therapy was discontinued, 21 patients
(84%) in arm A and 18 (75%) in arm B received systemic
chemotherapy. Among the 20 patients who received
maintenance therapy, 10 (83.3%) in arm A and 5 (62.5%)
in arm B received post-protocol therapy. EGFR tyrosine
kinase inhibitors were most commonly used (12 patients
in arm A and 10 in arm B). Pemtrexed and docetaxel
tended to be more frequently used in arm A (10 and 15,
respectively) than arm B (5 for each). Among 10 patients
in arm B who dropped out protocol treatment during in-
duction phase by the reason other than PD, 4 continued
to receive gemcitabine plus carboplatin combination ther-
apy as off-protocol treatment. No patient was treated with
any maintenance therapy as post-protocol treatment.
Discussion
Our study was launched on the assumption that gemcita-
bine monotherapy introduced immediately after standard
induction platinum-doublet chemotherapy is a promising
candidate for maintenance therapy for advanced NSCLC.
There was no significant difference in the transit rate
to maintenance phase and treatment response during in-
duction phase between the two arms of our study.
Table 3 Toxicities during induction chemotherapy
arm A (n = 25) arm B (n = 24)
Grade 1 2 3 4 1 2 3 4
Leukopenia 1 2 1 - - 2 2 1
Neutropenia - - 8 9 - 1 5 4
Neutropenic fever - - 1 - - - - -
Thrombocytopenia - - - - 1 4 1 2
Amenia 1 - - - - - 1 -
Low Hemoglobin - - - - 1 2 - -
AST/ALT 3 2 1 - - 2 3 -
Nausea 3 1 - - 3 1 - -
Pain - - - - 1 1 - -
Arthralgia 2 2 - - - - - -
Myalgia 2 3 - - - - - -
Skin rash 1 2 1 - 1 2 1 -
Conspitation 2 - - - 3 - - -
Fever 2 - - - - 2 - -
Fatigue 3 1 - - 1 1 - -
Peripheral Neurotoxicies 2 1 2 - - - - -
Pruritus - 1 - - - 1 - -
Appetite loss 1 2 - - 1 1 - -
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arm A received maintenance therapy, which was not in-
ferior to the percentage (33.6%, 73/217) of those who
transited to weekly paclitaxel continuation-maintenance
from 4 cycles of carboplatin plus tri-weekly paclitaxel in
a phase III study by Belani et al. [21]. On the other hand,
only 33.0% of patients in arm B could receive mainten-
ance therapy, which was lower than 54.8% (309/563) in a
phase III study by Fidias et al. that had comparedTable 4 All toxicities of grade 1-4 and severe toxicities of gra





reduced Hb 1 -
Anemia 1 -
Peripheral neurotoxicities 1 -
Skin rash 1 -
Fever 1 -
Pain 1 -
Cutaneous injection reaction 1 -
Liver abnormality 2 -
Complicated pneumonia 1 -immediate versus delayed docetaxel monotherapy after 4
cycles of induction carboplatin plus gemcitabine [4]. As
for treatment response to induction chemotherapy of
carboplatin plus tri-weekly paclitaxel, the RR (36.0%) in
arm A of our study was superior to that (19.2%) in the
study by Belani et al. [21]. On the other hand, in com-
parison of the RR for carboplatin plus gemcitabine,
16.7% in arm B of our study was lower than 31.1%
(168/563) in Fidias’s trial [4], but similar to 20.3% (13/64)
in a randomized phase II study of West Japan Thoracic
Oncology Group 0104 trial [22]. The most probable rea-
son for these differences between the two arms of our
study was that more patients were withdrawn from the
protocol study due to AEs in arm B (n = 9) than in arm
A (n = 1) and most of them (n = 7) were not assessable
for the response evaluation in arm B, despite that there
were no statistical differences in AEs between the two
arms except that the peripheral sensory neuropathy was
more frequent and severer in arm A. Furthermore, the
certain cause of more frequent withdrawal in arm B was
that discontinuation criteria were much stricter for arm B
than arm A, because neither omission nor delay longer
than 2 weeks of gemcitabine administration on day 8 was
permitted.
The applicability of gemcitabine for maintenance use
remains unestablished. There were 2 randomized phase
III studies that had compared gemcitabine maintenance
with best supportive care (BSC) in a continuation-
maintenance setting after achieving objective response
or disease stabilization by 4 cycles of initial gemcitabine
plus platinum therapy for advanced NSCLC [6,7]. Both
the studies showed that gemcitabine maintenance ther-
apy significantly prolonged the time-to-progression
(TTP) or PFS, but failed to improve the OS. In one study
by Brodowicz et al., the median TTP from the time ofde 3-4 during gemcitabine maintenance
arm A (n = 12) arm B (n = 8)
G1-4 G3-4 G1-4 G3-4
1 - - -
3 3 3 2
3 1 - -
- - 1 -
1 - - -
1 - - -
1 - - -
1 - - -
- - 1 -
- - 1 -
2 - - -
1 - - -
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months for BSC arms (p < 0.001), while median OS
throughout study was 13.0 months for gemcitabine and
11.0 months for BSC arms (p = 0.195). Compared with
this study, our study was inferior in PFS, but similar in
OS. We could not compare our study with the other
study by Perol et al. because neither PFS nor OS from
the enrollment was reported. In addition, the median
and average numbers of cycles of delivered gemcitabine
in maintenance phase in our study were 4 and over 5.5,
respectively, which were larger than median 3 cycles in
the study by Brodowicz et al. [5] and similar to median 4
cycles in the study by Perol et al. [6]. Noteworthily,
among 20 patients who received maintenance chemo-
therapy in our study, only 4 patients dropped out be-
cause they could not meet the criteria of the next course
due to AEs. Thus, gemcitabine is characteristically well-
tolerated and little cumulatively toxic, which enabled
patients to continue the maintenance treatment for a
longer time.
Pemetrexed [7] and bevacizumab [11] have been re-
cently approved for non-squamous NSCLC as a main-
tenance therapy or a first-line treatment in combination
with platinum-based chemotherapy. Maintenance ther-
apy using these two drugs has been shown to bring
about a significant survival benefit. In contrast, there are
few effective drugs with enough evidences as mainten-
ance therapy for NSCLC patients with squamous hist-
ology. Unlike pemetrexed and bevacizumab, gemcitabine
has antitumor efficacy against squamous NSCLC. There-
fore, a study evaluating gemcitabine as a maintenance
therapy specific for squamous histology seems very
interesting and promising.
Conclusions
In conclusion, our study suggested that gemcitabine may
be one of suitable drugs for maintenance therapy be-
cause of its well-tolerability and little cumulative tox-
icity. A study evaluating gemcitabine as a maintenance
therapy is expected especially in patients with squamous
NSCLC histology, for which few beneficial evidences
have been demonstrated.
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